Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT04089163
Previous Study | Return to List | Next Study

A Study of Toca 511 & Toca FC in Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer (Toca 8)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04089163
Recruitment Status : Not yet recruiting
First Posted : September 13, 2019
Last Update Posted : September 13, 2019
Sponsor:
Information provided by (Responsible Party):
Tocagen Inc.

Brief Summary:
This is a Phase 1, multicenter, open-label study of intravesical Toca 511 followed by oral Toca FC in patients with high grade (HG) non-muscle invasive bladder cancer (NMIBC), with cohort expansion at the recommended Phase 2 dose. Patients with recurrent HG NMIBC who are undergoing planned transurethral resection of bladder tumor (TURBT) will be enrolled into the study, subject to meeting all entry criteria.

Condition or disease Intervention/treatment Phase
Bladder Cancer Biological: Toca 511 Drug: Toca FC (extended-release formulation of flucytosine) Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Intervention Model: Sequential Assignment
Intervention Model Description: 3+3 dose escalation design with expansion at recommended Phase 2 dose.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Toca 8: A Multicenter, Open-Label, Phase 1 Study to Evaluate the Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer
Estimated Study Start Date : December 2019
Estimated Primary Completion Date : January 2022
Estimated Study Completion Date : January 2027

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bladder Cancer
Drug Information available for: Flucytosine

Arm Intervention/treatment
Experimental: Sequential Dose Cohorts
Doses of Toca 511 will be evaluated in sequential cohorts. Toca 511 will be administered as a single intravesical instillation. Following Toca 511 administration, Toca FC will be administered orally at a dose of 220 mg/kg/day for 7 days every 6 weeks.
Biological: Toca 511
Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal drug, flucytosine (5-fluorocytosine; 5-FC) to the anticancer drug 5-fluorouracil (5-FU) in cancer cells that have been infected by the Toca 511 vector.
Other Names:
  • vocimagene amiretrorepvec
  • retroviral replicating vector (RRV)

Drug: Toca FC (extended-release formulation of flucytosine)
Toca FC is an extended-release formulation of flucytosine and is supplied as 500 mg tablets
Other Names:
  • flucytosine
  • 5-fluorocytosine (5-FC)




Primary Outcome Measures :
  1. Dose-limiting toxicities [ Time Frame: 5 weeks ]
    • Any treatment-related Grade 3 or higher non-hematologic toxicity, excluding nausea, vomiting, or diarrhea that are controllable with appropriate medical measures (eg, antiemetics, antimotility drugs)
    • Any treatment-related Grade 4 or higher hematologic toxicity


Secondary Outcome Measures :
  1. Differences in viral transduction of Toca 511 at each dose level, based on quantitation of viral RNA and DNA in tumor [ Time Frame: 3 weeks (+/- 1 week) ]
  2. Clearance of viral RNA in plasma and urine, based on real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR), and of viral DNA in whole blood and urine, based on quantitative PCR (qPCR) [ Time Frame: 1 week for plasma, 4 weeks for urine ]

Other Outcome Measures:
  1. Changes from baseline in immune activity in tumor, peripheral blood, and urine [ Time Frame: 21 weeks ]
  2. Complete response rate at 6 and 12 months in patients with carcinoma in situ (CIS) [ Time Frame: Proportion of patients with CIS with complete response at 6 and 12 months ]
  3. High-grade recurrence-free survival [ Time Frame: Event free survival overall and at 6 and 12 months ]
  4. Incidence of cystectomy [ Time Frame: The proportion of patients who undergo cystectomy ]
  5. Incidence of disease progression at 6 and 12 months [ Time Frame: The proportion of patients with disease progression at 6 and 12 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Provide written informed consent to participate
  • At least 18 years of age
  • Recurrent HG NMIBC, with HG tumor on previous histopathology
  • Undergoing planned TURBT and biopsy of CIS suspicious areas
  • No imaging findings consistent with T2 or greater disease, hydronephrosis, extravesical disease, nodal involvement, metastases, or other malignancies.
  • Able and willing to wait at least 2 weeks following intravesical administration of Toca 511 to undergo TURBT
  • If patient is a candidate for standard of care (SOC) intravesical therapy, able and willing to wait at least 2 weeks post-TURBT for initiation of such treatment
  • Patient is able to be catheterized and is anticipated to be able to retain Toca 511 for approximately 2 hours
  • Estimated life expectancy of at least 12 months
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
  • Patient has adequate organ function, as indicated by the following laboratory values

    • Complete blood count: hemoglobin ≥ 10 g/dL, platelet count ≥ 100,000/mm^3, absolute neutrophil count ≥ 1,500/ mm^3, absolute lymphocyte count ≥ 500/ mm^3
    • Liver: total bilirubin ≤ 1.5 × the upper limit of normal (ULN; unless known Gilbert's syndrome); alanine aminotransferase ≤ 2.5 × ULN
    • Kidney: estimated glomerular filtration rate (GFR: Cockcroft-Gault) ≥ 50 mL/min
  • Women of childbearing potential (defined as not postmenopausal [ie, ≥ 12 months of non-therapy-induced amenorrhea] or not surgically sterile) must have a negative serum pregnancy test within 7 days prior to administration of Toca 511, and be willing to use an effective means of contraception in addition to barrier methods (condoms) for the duration of the study.
  • Patient and partner are willing to use condoms for 12 months after receiving Toca 511 and/or 30 days after the last dose of Toca FC, and/or until there is no evidence of the virus in his/her blood or urine, whichever is longer.

Exclusion Criteria:

  • History of urothelial cancer in the upper tract or urethra; muscle invasive bladder cancer; or metastatic bladder cancer
  • History of bladder tumors other than urothelial carcinoma (ie, neuroendocrine, adenocarcinoma, or squamous cell carcinoma)
  • Treatment with intravesical agents within 28 days prior to Toca 511 administration
  • TURBT within 12 weeks prior to planned Toca 511 administration
  • History of pelvic radiation
  • Bladder tumor located within a bladder diverticulum
  • Genitourinary procedures (eg, prostate surgery; treatment of ureteral stones or moderate to extensive urethral stricture disease) prior to, during, or planned within the 4 weeks following TURBT, other than procedures for treatment of bladder tumors
  • Severe lower urinary tract dysfunction clinically manifest as poor capacity, disabling incontinence, chronic catheter use, or chronic infections or stones
  • Presence of suprapubic catheter
  • History of other malignancy, unless the patient has been disease-free for at least 5 years. Adequately treated basal cell carcinoma or squamous cell skin cancer is acceptable regardless of time, as well as cervical carcinoma in situ or localized prostate carcinoma, after curative treatment. (Note: Men with very low or low risk prostate cancer on active surveillance are acceptable candidates for this study.)
  • Active infection requiring antibiotic, antifungal, or antiviral therapy within 2 weeks prior to administration of Toca 511
  • Investigational treatment within 2 weeks or immunotherapy or antibody therapy within 28 days prior to Toca 511 administration, and/or has not recovered from toxicities associated with such treatment
  • Chronic treatment with autoimmune medications
  • Human immunodeficiency virus (HIV) seropositive
  • Pregnant or breast feeding
  • Bleeding diathesis, or required to take anticoagulants or antiplatelet agents, including nonsteroidal anti-inflammatory drugs, that cannot be stopped for surgery
  • Severe pulmonary, cardiac, or other systemic disease, specifically:

    • New York Heart Association > Class II congestive heart failure that is not controlled on standard therapy within 6 months prior to Toca 511 administration
    • Uncontrolled or significant cardiovascular disease, clinically significant ventricular arrhythmia (such as ventricular tachycardia, ventricular fibrillation, or torsades de pointes), clinically significant pulmonary disease (such as ≥ Grade 2 dyspnea)
    • Any other serious medical, social, or psychological condition that, based on Investigator assessment, may affect the patient's compliance or place the patient at an increased risk of potential treatment complications
  • History of allergy or intolerance to flucytosine
  • Presence of a condition that would prevent the patient from being able to swallow Toca FC tablets

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04089163


Contacts
Layout table for location contacts
Contact: Sharon Yavrom, Ph.D. (858) 412-8461 syavrom@tocagen.com
Contact: Jose Martinez, M.D. (858) 412-8434 jmartinez@tocagen.com

Sponsors and Collaborators
Tocagen Inc.

Layout table for additonal information
Responsible Party: Tocagen Inc.
ClinicalTrials.gov Identifier: NCT04089163     History of Changes
Other Study ID Numbers: Tg 511-19-01
First Posted: September 13, 2019    Key Record Dates
Last Update Posted: September 13, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Tocagen Inc.:
non-muscle invasive bladder cancer
bladder cancer
high grade non-muscle invasive bladder cancer
HG NMIBC
NMIBC
high grade NMIBC
Additional relevant MeSH terms:
Layout table for MeSH terms
Urinary Bladder Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Urinary Bladder Diseases
Urologic Diseases
Flucytosine
Antifungal Agents
Anti-Infective Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action